About this Journal Submit a Manuscript Table of Contents
ISRN Dermatology
Volume 2012 (2012), Article ID 460467, 6 pages
http://dx.doi.org/10.5402/2012/460467
Clinical Study

Assessment of the Efficacy and Safety of a New Treatment for Head Lice

1Skinexigence, Pavillon Sainte-Lucienne, Saint-Jacques University Hospital, 25030 Besançon, France
2Research and Studies Centre on the Integument (CERT), Department of Dermatology, Saint-Jacques University Hospital, University of Franche-Comté and INSERM UMR1098, SFR FED 4234 IBCT, 25000 Besançon, France
3Dermlink International Ltd., Grosvenor Gardens House, 35/37 Grosvenor Gardens, London SW1W 0BS, UK
4Rausch AG, Bärenstraße 12, 8280 Kreuzlingen, Switzerland

Received 21 June 2012; Accepted 14 August 2012

Academic Editors: C. De La Torre, C. Feliciani, C.-C. Lan, and E. Pasmatzi

Copyright © 2012 Sophie Mac-Mary et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Infestation with head lice is a widespread, persistent, and recurring issue leading to serious health problems if untreated. We are facing resistance phenomena to usual pediculicides and questions about their direct or cumulative toxicity. The aim of this trial was to assess the efficacy of a new product, free of chemical insecticides but with a physical effect. This product contains components whose antilice efficacy has already been demonstrated, as well as Andiroba oil which asphyxiates the lice and Quassia vinegar which dissolves the chitin of the nits (they are then inactivated). 30 patients with head lice infestation, aged 3–39 years, applied the treatment one to three times, 5 days apart. Cure was defined as the absence of live lice after 5, 10, or 14 days, and symptoms are usually associated with infestation. Easiness and safety of the treatment were assessed by the patients and/or their parents. Overall cure rates were 20% on D5 after one treatment, 37% on D10 after two treatments, and 90% on D14 after three treatments. Symptoms such as itch, scalp dryness, redness, and flakiness rapidly diminished. This treatment seems to be a beneficial addition or a valuable alternative to existing treatments, considering the total absence of chemical insecticides, the absence of drug-resistance induction in head lice, the absence of major toxicological risks compared with usual pediculicides, and the favourable patient use instructions.